Busey Trust CO increased its stake in Celgene Corporation (NASDAQ:CELG) by 2.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,358 shares of the biopharmaceutical company’s stock after buying an additional 1,480 shares during the period. Busey Trust CO’s holdings in Celgene Corporation were worth $7,635,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Pictet Asset Management Ltd. increased its stake in shares of Celgene Corporation by 7.9% in the first quarter. Pictet Asset Management Ltd. now owns 2,265,317 shares of the biopharmaceutical company’s stock worth $281,873,000 after buying an additional 165,159 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of Celgene Corporation by 0.7% in the first quarter. Handelsbanken Fonder AB now owns 444,449 shares of the biopharmaceutical company’s stock worth $55,303,000 after buying an additional 3,000 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in shares of Celgene Corporation by 14.6% in the first quarter. Xact Kapitalforvaltning AB now owns 171,725 shares of the biopharmaceutical company’s stock worth $21,368,000 after buying an additional 21,839 shares in the last quarter. Trust Co. of Vermont increased its stake in shares of Celgene Corporation by 1.4% in the first quarter. Trust Co. of Vermont now owns 46,698 shares of the biopharmaceutical company’s stock worth $5,811,000 after buying an additional 659 shares in the last quarter. Finally, Nelson Roberts Investment Advisors LLC increased its stake in shares of Celgene Corporation by 2.0% in the first quarter. Nelson Roberts Investment Advisors LLC now owns 25,205 shares of the biopharmaceutical company’s stock worth $3,136,000 after buying an additional 500 shares in the last quarter. 78.39% of the stock is owned by institutional investors.

Celgene Corporation (CELG) traded up 0.78% on Thursday, reaching $135.90. 2,838,895 shares of the company’s stock traded hands. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00. The firm has a market cap of $106.32 billion, a price-to-earnings ratio of 42.20 and a beta of 1.89. The stock’s 50 day moving average is $132.00 and its 200 day moving average is $123.32.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the firm posted $1.44 earnings per share. The business’s revenue was up 18.7% on a year-over-year basis. On average, equities research analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/03/celgene-corporation-celg-position-raised-by-busey-trust-co-updated-updated-updated.html.

A number of equities research analysts recently weighed in on the stock. Mizuho set a $134.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. Robert W. Baird reaffirmed an “outperform” rating and set a $162.00 price objective on shares of Celgene Corporation in a research report on Friday, July 21st. Jefferies Group LLC reaffirmed a “buy” rating and set a $160.00 price objective on shares of Celgene Corporation in a research report on Monday. Finally, Cann restated a “buy” rating and issued a $175.00 target price on shares of Celgene Corporation in a research report on Tuesday. One analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have given a buy rating to the company’s stock. Celgene Corporation currently has an average rating of “Buy” and a consensus target price of $147.06.

In other news, insider Robert J. Hugin sold 175,970 shares of Celgene Corporation stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the sale, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 227,755 shares of company stock worth $30,368,142. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.